“[Budget impact analysis of idarucizumab for the management of patients treated with dabigatran in emergency / urgent situations in Italy]” (2016) Farmeconomia. Health economics and therapeutic pathways, 17(2), pp. 47–58. doi:10.7175/fe.v17i2.1243.